Literature DB >> 14534366

Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.

Guo-Min Zhao1, Xuanxuan Qian, Peter W Schiller, Hazel H Szeto.   

Abstract

[Dmt1]DALDA (H-Dmt-d-Arg-Phe-Lys-NH2; Dmt = 2',6'-dimethyltyrosine) binds with high affinity and selectivity to the mu opioid receptor and is a surprisingly potent and long-acting analgesic, especially after intrathecal administration. In an attempt to better understand the unique pharmacological profile of [Dmt1]DALDA, we have prepared [3H][Dmt1]DALDA and compared its binding properties with that of [3H]DAMGO ([d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin). Kinetic studies revealed rapid association of [3H][Dmt1]DALDA when incubated with mouse brain membranes (K+1 = 0.155 nM(-1) min(-1)). Dissociation of [3H][Dmt1]DALDA was also rapid (K(-1) = 0.032 min(-1)) and indicated binding to a single site. [3H][Dmt1]DALDA binds with very high affinity to human mu opioid receptor (hMOR) (Kd = 0.199 nM), and Kd and Bmax were reduced by sodium but not Gpp(NH)p [guanosine 5'-(beta,gamma-imido)triphosphate]. Similar Kd values were obtained in brain and spinal cord tissues and SH-SY5Y cells. The hMOR:hDOR (human delta opioid receptor) selectivity of [Dmt1]DALDA ( approximately 10,000) is 8-fold higher than DAMGO. However, [Dmt1]DALDA is less selective than DAMGO against hKOR (human kappa opioid receptor) (26-versus 180-fold). The Ki values for a number of opioid ligands were generally higher when determined by competitive displacement binding against [3H][Dmt1]DALDA compared with [3H]DAMGO, with the exception of Dmt1-substituted peptide analogs. All Dmt1 analogs showed much higher affinity for the mu receptor than corresponding Tyr1 analogs. [35S]GTPgammaS (guanosine 5'-O -(3-[35S]thio)triphosphate) binding showed that [Dmt1]DALDA and DAMGO are full agonists at hMOR and hDOR but are only partial agonists at hKOR. The very high affinity and selectivity of [3H][Dmt1]DALDA for the mu receptor, together with its very low nonspecific binding (10-15%) and metabolic stability, make [3H][Dmt1]DALDA an ideal radioligand for labeling mu receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534366     DOI: 10.1124/jpet.103.054775

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

Review 1.  In vitro and direct in vivo testing of mixture-based combinatorial libraries for the identification of highly active and specific opiate ligands.

Authors:  Richard A Houghten; Colette T Dooley; Jon R Appel
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

2.  Design, synthesis and evaluation of 111In labeled DOTA-conjugated tetrapeptides having high affinity and selectivity for mu opioid receptors.

Authors:  John R Lever; Emily A Fergason-Cantrell; Terry L Carmack; Lisa D Watkinson; Fabio Gallazzi
Journal:  Nucl Med Biol       Date:  2019-03-07       Impact factor: 2.408

3.  Mast Cell Degranulation and Fibroblast Activation in the Morphine-induced Spinal Mass: Role of Mas-related G Protein-coupled Receptor Signaling.

Authors:  Tony L Yaksh; Kelly A Eddinger; Shinichi Kokubu; Zhenping Wang; Anna DiNardo; Roshni Ramachandran; Yuelian Zhu; Yajun He; Fieke Weren; Daphne Quang; Shelle A Malkmus; Katherine Lansu; Wesley K Kroeze; Brian Eliceiri; Joanne J Steinauer; Peter W Schiller; Peter Gmeiner; Linda M Page; Keith R Hildebrand
Journal:  Anesthesiology       Date:  2019-07       Impact factor: 7.892

4.  Mu Opioid Receptor Agonist DAMGO Produces Place Conditioning, Abstinence-induced Withdrawal, and Naltrexone-Dependent Locomotor Activation in Planarians.

Authors:  Emily Dziedowiec; Sunil U Nayak; Keenan S Gruver; Tyra Jennings; Christopher S Tallarida; Scott M Rawls
Journal:  Neuroscience       Date:  2018-06-27       Impact factor: 3.590

5.  Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease.

Authors:  P Hemachandra Reddy; Maria Manczak; XiangLing Yin; Arubala P Reddy
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.

Authors:  Hazel H Szeto; Peter W Schiller
Journal:  Pharm Res       Date:  2011-06-03       Impact factor: 4.200

7.  Psychedelics and the human receptorome.

Authors:  Thomas S Ray
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

8.  Standard opioid agonists activate heteromeric opioid receptors: evidence for morphine and [d-Ala(2)-MePhe(4)-Glyol(5)]enkephalin as selective μ-δ agonists.

Authors:  Ajay S Yekkirala; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  ACS Chem Neurosci       Date:  2009-11-25       Impact factor: 4.418

9.  micro-Opioid receptor stimulation in the medial subnucleus of the tractus solitarius inhibits gastric tone and motility by reducing local GABA activity.

Authors:  Melissa A Herman; Alisa Alayan; Niaz Sahibzada; Barbara Bayer; Joseph Verbalis; Kenneth L Dretchen; Richard A Gillis
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-05-20       Impact factor: 4.052

10.  Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson's disease.

Authors:  Ana Navarro; Alberto Boveris
Journal:  Front Aging Neurosci       Date:  2010-09-01       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.